Table 2.
Mean ± standard deviation (SD) strongyle-type fecal egg count (FEC), mean percent fecal egg count reduction (FECR%), and mucous membrane scores by treatment group and time period
| Groupa | Mean ± SD nematode FEC pre-treatment (eggs/gram)b | Mean ± SD nematode FEC 10 d later (eggs/gram)c | Mean FECR% (95% CI) | Mean ± SD mucous membrane score pre-treatment | Mean ± SD mucous membrane score 10 d later |
|---|---|---|---|---|---|
| Doramectin 0.2 mg/kg BW SQ (n = 9) | 952 ± 669 | 626 ± 720 | 34 (−16 to 85) | 3.0 ± 1.2 | 2.9 ± 0.9 |
| Fenbendazole 10 mg/kg BW PO (n = 9) | 1104 ± 1018 | 2328 ± 5024 | −111 (±377 to 156)d | 3.4 ± 1.2 | 2.8 ± 1.5 |
| Albendazole 10 mg/kg BW PO (n =10) | 1291 ± 1422 | 524 ± 833 | 59 (3 to 116) | 3.9 ± 1.3 | 3.5 ± 1.0 |
BW — body weight; SD — standard deviation; PO — per os; SQ — subcutaneous; 95% CI — 95% confidence interval; FEC — fecal egg count; FECR — fecal egg count reduction.
a
Label dosages for cattle.
b
No significant difference in mean pre-treatment FEC between groups [one-way analysis of variance (ANOVA), P = 0.80].
c
No significant difference in mean follow-up FEC between groups (one-way ANOVA, P = 0.35).
d
Two animals in this group had a ≥ 5-fold increase in fecal egg count after treatment, thus impacting overall mean FECR%.